ASO Visual Abstract: Risk of Surgical Overtreatment in cN1 Breast Cancer Patients Who Become ypN0 After Neoadjuvant Chemotherapy: SLNB Versus TAD.

Competing Interests: Disclosure: Elizabeth A. Mittendorf reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck, and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via an SU2C grant) and Gilead. She also reports research funding from Susan Komen for the Cure, for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. Tari A. King reports speaker honoraria for Exact Sciences; compensated service on the FES Steering Committee and GE Healthcare; and compensated service as faculty for PrecisCa cancer information service. Alison Laws, Saskia Leonard, Julie Vincuilla, Tonia Parker, Olga Kantor, and Anna Weiss declare no conflicts of interest that may be relevant to the contents of this study.